Alport Syndrome Market is Driven by Gene Therapy Advances
Alport syndrome is a rare progressive renal disease characterized by inherited defects in type IV collagen, leading to hematuria, proteinuria and eventual kidney failure. The Alport Syndrome Market comprises a diverse portfolio of therapeutics, including symptomatic treatments such as ACE inhibitors, emerging small molecules, biologics targeting fibrosis pathways and novel gene therapies...
0 Σχόλια 0 Μοιράστηκε 101 Views 0 Προεπισκόπηση